Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER-T2D: Obesity-centric Management in T2D
NCT04531176Phase 4Terminated
- Sponsor
- Cleveland Clinic
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide, phentermine + topiramate, naltrexone + bupropion, orlistat in obesity, sponsored by Cleveland Clinic. Started Sep 2020; status: terminated.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04531176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531176.